Matt Riley
Senior Director of Investor Relations
Replay available
PAVmed Inc. (NASDAQ: PAVM) Q1 2025 earnings conference call, held 2025-05-15. Replay captured from the company's public earnings webcast.

Senior Director of Investor Relations
Chairman and Chief Executive Officer of PavMed
Chief Financial Officer of PavMed
Analyst, Maxim Group
Good morning and welcome to the PAVMED first quarter 2025 business update conference call. At this time, all lines are in listen only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. Please note this event is being recorded. I would now like to turn the conference over to Matt Riley, I have met Senior Director of Investor Relations. Please go ahead. Thank you, Operator, and good morning, everyone. Thank you for participating in today's business update call. Joining me today on the call are Dr. Alicia Nacog, Chairman and Chief Executive Officer of PavMed, along with Dennis McGrath, Chief Financial Officer of PavMed. The press release announcing our business update and financial results is available on PABMED's website. Please take a moment to read the disclaimers about forward-looking statements in the press release. The business update, press release, and the conference call all include forward-looking statements, and these forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from statements made. Factors that could cause actual results to differ are described in the disclaimer and in our filings with the SEC. For a list and a description of these and other important risks and uncertainties that may affect future operations, see Part 1, Item 1A, entitled Risk Factors in PAVMED's most recent annual report on Forms 10-K, filed with the FCC, and any subsequent updates filed in quarterly reports on Forms 10-Q and subsequent Forms 8-K. Except as required by law, PAVMED disclaims any intentions or obligations to publicly update or revise any four different...